Ergoteles’s Nurix Therapeutics NRIX Stock Holding History

Ergoteles’s Portfolio NRIX Stock Details NRIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-48,494	Closed	-$431K	–	1350
2023 Q1	$431K	Buy	+48,494	New	+$505K	0.02%	787

Other funds holding NRIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Ergoteles's NRIX Position: Q2 2023 in Review

Ergoteles sold out of Nurix Therapeutics (NRIX) in Q2 2023, closing a stake of 48,494 shares — an estimated $431K sold.

Ergoteles first reported a position in NRIX in Q1 2023 and held it in 1 quarter. The position peaked at $431K in Q1 2023. 126 funds tracked by Wall St. Rank hold NRIX as of Q2 2023.

Ergoteles reported no remaining Nurix Therapeutics position as of Q2 2023 after selling out during the quarter.
Ergoteles sold 48,494 Nurix Therapeutics shares in Q2 2023, an estimated $431K.
Ergoteles first reported a position in Nurix Therapeutics in Q1 2023 and held it in 1 quarter.
Ergoteles's Nurix Therapeutics position peaked at $431K in Q1 2023.
126 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2023.

Based on Ergoteles's 13F filing for Q2 2023, filed 14 Aug 2023.